The U.S. Trade Representative’s Special 301 report uses new, tougher language to call out a handful of countries for using or threatening to use compulsory licenses, which USTR says is undermining rights holders and forcing American patients to fund research and development for new drugs. If a country issues a compulsory license, companies are allowed to produce a patented product without the consent of the rights holder. Past renditions of the Special 301 report have singled out countries for utilizing...